Patents by Inventor Grigorios Nikitidis

Grigorios Nikitidis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLOPENTANE COMPOUNDS
    Publication number: 20220194922
    Abstract: The present invention relates to cyclopentane compounds of Formula (I), physical forms thereof, processes for their production and their use in medicine.
    Type: Application
    Filed: December 27, 2021
    Publication date: June 23, 2022
    Inventors: Xiaolin ZHANG, Weitao PAN, Grigorios NIKITIDIS, Jenny Susanna Marika LINDHAGEN
  • Cyclopentane compounds
    Patent number: 11274091
    Abstract: The present invention relates to cyclopentane compounds of Formula (I), physical forms thereof, processes for their production and their use in medicine.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: March 15, 2022
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Xiaolin Zhang, Weitao Pan, Grigorios Nikitidis, Jenny Susanna Marika Lindhagen
  • Chemical compounds
    Patent number: 10954211
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 23, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • CYCLOPENTANE COMPOUNDS
    Publication number: 20210070733
    Abstract: The present invention relates to cyclopentane compounds of Formula (1), physical forms thereof, processes for their production and their use in medicine.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 11, 2021
    Inventors: Xiaolin ZHANG, Weitao PAN, Grigorios NIKITIDIS, Jenny Susanna Marika LINDHAGEN
  • Chemical Compounds
    Publication number: 20190330187
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Application
    Filed: May 10, 2019
    Publication date: October 31, 2019
    Inventors: Susanne Elisabeth BERGLUND, Stephen CONNOLLY, Martin HEMMERLING, Nafizal HOSSAIN, Anna KRISTOFFERSSON, Johan Rune Michael LUNDKVIST, Grigorios NIKITIDIS, Lena Elisabeth RIPA, Igor SHAMOVSKY
  • Chemical compounds
    Patent number: 10336725
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: July 2, 2019
    Assignee: AstraZeneca AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • Chemical Compounds
    Publication number: 20180162838
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Application
    Filed: December 13, 2017
    Publication date: June 14, 2018
    Inventors: Susanne Elisabeth BERGLUND, Stephen CONNOLLY, Martin HEMMERLING, Nafizal HOSSAIN, Anna KRISTOFFERSSON, Johan Rune Michael LUNDKVIST, Grigorios NIKITIDIS, Lena Elisabeth RIPA, Igor SHAMOVSKY
  • Chemical compounds
    Patent number: 9873678
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: January 23, 2018
    Assignee: AstraZeneca AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • COMPOUNDS AND USES
    Publication number: 20170216283
    Abstract: There is provided compounds of formula I, wherein E1, E2, E3, E4, L1, Y1, Y2, Y3, Ra and z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Applicant: AstraZeneca AB
    Inventors: Robert Ronn, Carl Jonas Lindh, Erik Ringberg, Hanna Birgitta Ellinor Andersson, Peter Nilsson, Wesley Ralph Schaal, Magnus Munck af Rosenschöld, Antonios Nikitidis, Grigorios Nikitidis, Petra Johannesson, Christian Tyrchan
  • Compounds and uses
    Patent number: 9657001
    Abstract: There is provided compounds of formula I, wherein E1, E2, E3, E4, L1, Y1, Y2, Y3, Ra and z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: May 23, 2017
    Assignee: ASTRAZENECA AB
    Inventors: Robert Ronn, Carl Jonas Lindh, Erik Ringberg, Hanna Birgitta Ellinor Andersson, Peter Nilsson, Wesley Ralph Schaal, Magnus Munck af Rosenschöld, Antonios Nikitidis, Grigorios Nikitidis, Petra Johannesson, Christian Tyrchan
  • Chemical Compounds
    Publication number: 20170107195
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Application
    Filed: March 17, 2015
    Publication date: April 20, 2017
    Applicant: AstraZeneca AB
    Inventors: Susanne Elisabeth BERGLUND, Stephen CONNOLLY, Martin HEMMERLING, Nafizal HOSSAIN, Anna KRISTOFFERSSON, Johan Rune Michael LUNDKVIST, Grigorios NIKITIDIS, Lena Elisabeth RIPA, Igor SHAMOVSKY
  • COMPOUNDS AND USES
    Publication number: 20160326143
    Abstract: There is provided compounds of formula I, wherein E1, E2, E3, E4, L1, Y1, Y2, Y3, Ra and z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 10, 2016
    Applicant: AstraZeneca AB
    Inventors: Robert Ronn, Carl Jonas Lindh, Erik Ringberg, Hanna Birgitta Ellinor Andersson, Peter Nilsson, Wesley Ralph Schaal, Magnus Munck af Rosenschöld, Antonios Nikitidis, Grigorios Nikitidis, Petra Johannesson, Christian Tyrchan
  • 5-heteroaryl thiazoles and their use as PI3K inhibitors
    Patent number: 7868188
    Abstract: The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R1, R2 and R3 are as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: January 11, 2011
    Assignee: AstraZeneca AB
    Inventors: Malena Bengtsson, Joakim Larsson, Grigorios Nikitidis, Peter Storm, John Peter Bailey, Edward Jolyon Griffen, Jean-Claude Arnould, Thomas Geoffrey Colerick Bird
  • Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors
    Publication number: 20090233907
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE 4 mediated disease state.
    Type: Application
    Filed: March 20, 2007
    Publication date: September 17, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Rupert Austin, Roger Victor Bonnert, Simon Fraser Hunt, Grigorios Nikitidis, Hitesh Jayantilal Sanganee, Peter Olof Sjo, Dan Warner
  • Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases
    Publication number: 20080227797
    Abstract: The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.
    Type: Application
    Filed: July 3, 2006
    Publication date: September 18, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Annea Lisius, Grigorios Nikitidis, Peter Sjo
  • Use of and some novel imidazopyridines
    Patent number: 7410966
    Abstract: The use of compounds of formula (I) wherein R1, R3, R10, m and Ar are as defined in the Specification and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is disclosed.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: August 12, 2008
    Assignee: AstraZeneca AB
    Inventors: Henrik Johansson, Karolina Lawitz, Grigorios Nikitidis, Peter Sjö, Peter Storm
  • 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors
    Publication number: 20080132502
    Abstract: The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R1, R2 and R3 are as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.
    Type: Application
    Filed: November 7, 2005
    Publication date: June 5, 2008
    Inventors: Malena Bengtsson, Joakim Larsson, Grigorios Nikitidis, Peter Storm, John Peter Bailey, Edward Jolyon Griffen, Jean-Claude Arnould, Thomas Geoffrey Colerick Bird
  • Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof
    Patent number: 7030246
    Abstract: Compounds of formula (I) are modulators of STAT6 signal pathway activity, and can be used in the treatment of atopic dermatitis, urticaria, allergic asthma, allergic rhinitis, a food allergy, allergic conjunctivitis, hayfever, bullous pemphigoid, industrial sensitization, chronic rejection of transplants or COPD
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: April 18, 2006
    Assignee: Astrazeneca AB
    Inventors: Håkan Bladh, Thomas Hansson, Grigorios Nikitidis, Carita Nordén, Lars Pettersson, Mikael Varga
  • 2-Pyridone derivatives as inhibitors of neutrophile elastase
    Publication number: 20060035938
    Abstract: There are provided novel compounds of formula (I) wherein R1?, R4?. R5?, G1?, G2?, X, L, Y1?, Y2? and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors or neutrophil elastase.
    Type: Application
    Filed: November 11, 2003
    Publication date: February 16, 2006
    Inventors: Hakan Bladh, Tomas Klingstedt, Joakim Larsson, Karolina Lawitz, Matti Lepisto, Hans Lonn, Grigorios Nikitidis
  • Use of and some novel imidazopyridines
    Publication number: 20050261333
    Abstract: The use of compounds of formula (I) wherein R1, R3, R10, m and Ar are as defined in the Specification and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is disclosed. Certain novel compounds of formula (I), together with processes for their preparation, compositions containing them and their use in therapy are also disclosed.
    Type: Application
    Filed: August 13, 2003
    Publication date: November 24, 2005
    Applicant: AstraZeneca A B
    Inventors: Henrik Johansson, Karolina Lawitz, Grigorios Nikitidis, Peter Sjo, Peter Storm